Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

NCT03706547 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma in Relapse
Multiple Myeloma Progression

Interventions

BIOLOGICAL: anti-CD19/BCMA CAR-T cells
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Peng Liu

Collaborators

[object Object]
[object Object]